Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEATION: ctDNA-guided consolidation immunotherapy in Stage III NSCLC
NCT07759492Phase 2Not yet recruiting
- Sponsor
- IFCT
- Start
- Nov 2026
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by IFCT. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07759492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07759492.